Abstract
For many years, the interleukin-1 receptor family member ST2 was an orphan receptor that was studied in the context of inflammatory and autoimmune disease. However, in 2005, a new cytokine--interleukin-33 (IL-33)--was identified as a functional ligand for ST2. IL-33/ST2 signalling is involved in T-cell mediated immune responses, but more recently, an unanticipated role in cardiovascular disease has been demonstrated. IL-33/ST2 not only represents a promising cardiovascular biomarker but also a novel mechanism of intramyocardial fibroblast-cardiomyocyte communication that may prove to be a therapeutic target for the prevention of heart failure.
MeSH terms
-
Animals
-
Atherosclerosis / etiology
-
Atherosclerosis / metabolism
-
Biomarkers / metabolism
-
Disease Progression
-
Drug Delivery Systems / methods*
-
Drug Delivery Systems / trends
-
Humans
-
Interleukin-1 Receptor-Like 1 Protein
-
Interleukin-33
-
Interleukins / agonists
-
Interleukins / antagonists & inhibitors
-
Interleukins / metabolism
-
Interleukins / physiology*
-
Receptors, Cell Surface / agonists
-
Receptors, Cell Surface / antagonists & inhibitors
-
Receptors, Cell Surface / metabolism
-
Receptors, Cell Surface / physiology*
-
Signal Transduction / drug effects
-
Signal Transduction / physiology*
Substances
-
Biomarkers
-
IL1RL1 protein, human
-
IL33 protein, human
-
Interleukin-1 Receptor-Like 1 Protein
-
Interleukin-33
-
Interleukins
-
Receptors, Cell Surface